Capricor Therapeutics Investors Eye Class Action Ahead of September Deadline

Investors Take Note: Capricor Therapeutics Faces Class Action Deadline

In light of significant stock losses, Capricor Therapeutics, Inc. (NASDAQ: CAPR) is under scrutiny as its investors are urged to join a proposed class action lawsuit. According to Hagens Berman Sobol Shapiro LLP, a notable plaintiffs’ rights law firm, investors must act before the deadline on September 28, 2026, to register as lead plaintiffs in the ongoing securities class action.

This development follows the recent decision by the U.S. Food and Drug Administration (FDA) to extend the review period for Capricor’s Biologics License Application (BLA), casting further doubt on the company's financial viability and regulatory compliance.

Regulatory Scrutiny Developments

On August 24, 2026, Capricor released a statement informing investors of the FDA’s decision to push the action date for its lead investigational cell therapy, deramiocel, from August 22, 2026, to November 22, 2026. This delay was driven by concerns regarding the company's regulatory submissions and the implications of a turbulent Advisor Committee meeting earlier in July. The FDA classified this delay as a major amendment, underlining the ongoing regulatory issues that the company faces.

Investors who suffered noteworthy financial losses during the critical time frame from December 17, 2025, to July 26, 2026, are being encouraged to submit their claims now, as the potential for a settlement may offer recovery for aggrieved shareholders.

Details of the Securities Class Action

The core of the securities class action centers around allegations that Capricor's executives made misleading statements regarding the clinical trials for its lead product, deramiocel, which is designed to treat Duchenne muscular dystrophy (DMD). It is specifically alleged that the company did not fully disclose significant changes made to its pre-specified statistical analysis plan (SAP), which were undertaken without the FDA's consent.

The lawsuit outlines that on December 3, 2025, Capricor announced positive results from the pivotal Phase 3 HOPE-3 study, which reportedly showcased impressive advancements in treating DMD. This announcement caused a significant surge in stock price, reaching $23.60 per share, only to subsequently plummet nearly 64% following unfavorable revelations from the FDA in late July 2026.

Overview of the Fallout

On July 27, 2026, the FDA's briefing documents revealed that the HOPE-3 study did not meet its primary and secondary endpoint efficacies, leading to a dramatic collapse in Capricor’s stock price and a subsequent advisory committee vote against the efficacy of the drug. This turn of events has exacerbated losses among investors, triggering the current focus on potential legal avenues for recovery.

Reed Kathrein, a partner at Hagens Berman, emphasizes the firm’s commitment to uncovering how management characterized the trial endpoint changes, asserting that transparency is paramount in investor relations.

Next Steps for Affected Investors

Investors who acquired shares during the specified period and have seen considerable losses now face a crucial decision. To secure a lead plaintiff role, they must act by the September 28 deadline. However, participation in any potential recovery doesn't necessitate a lead plaintiff status; all affected investors are advised to consult legal options.

For those seeking further guidance, additional information about the lawsuit, along with contact details for Hagens Berman, can be accessed via their website. Investors are also encouraged to share information that may assist the investigation or consider the SEC’s Whistleblower program, offering protection and potential financial incentives for original information.

The situation remains fluid, and its impact on Capricor’s future is uncertain as the firm battles through these allegations and regulatory challenges. Investors are urged to remain informed and proactive in addressing their stakes in the burgeoning biotechnology sector as this case progresses.